Discover new hope for refractory follicular lymphoma with FDA-approved Brukinsa and Gazyva. This groundbreaking treatment offers improved outcomes for patients who have exhausted other options.

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma. Monjuvi is a humanized Fc ...

The approval was based off findings from the BGB-3111-212 (ROSEWOOD) clinical trial, that included 217 adults with pretreated relapsed or refractory follicular lymphoma. Two thirds of the patients ...

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.

Caimi explained that the findings showed that “1 year of the triplet combination seems to be better than the doublet in patients with relapsed follicular lymphoma.” Reference: Sehn LH, et al ...

Roche is seeking an FDA blessing for the CD20xCD3 bispecific for follicular lymphoma after at least two prior systemic therapies. Under the expedited review pathway, the FDA has set Dec. 29 as its ...

Upon the FDA approval for its bispecific antibody Lunsumio (mosunetuzumab) as a third-line therapy for follicular lymphoma, Roche was quick to point out that its treatment was an “off-the-shelf ...

Dec 23 (Reuters) - The U.S. health regulator has approved Roche Holding AG's (ROG.S), opens new tab therapy for treating a type of rare cancer called follicular lymphoma. The U.S. Food and Drug ...